Cantor Fitzgerald Comments on Verona Pharma FY2025 Earnings

Verona Pharma plc (NASDAQ:VRNA - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for Verona Pharma in a report released on Monday, April 21st. Cantor Fitzgerald analyst O. Brayer forecasts that the company will earn $0.11 per share for the year. Cantor Fitzgerald has a "Overweight" rating and a $80.00 price objective on the stock. The consensus estimate for Verona Pharma's current full-year earnings is ($1.95) per share.

Several other equities research analysts have also commented on the company. Canaccord Genuity Group boosted their price objective on Verona Pharma from $44.00 to $72.00 and gave the stock a "buy" rating in a research note on Wednesday, February 12th. Wells Fargo & Company increased their price objective on Verona Pharma from $74.00 to $93.00 and gave the company an "overweight" rating in a research note on Friday, February 28th. HC Wainwright lifted their target price on shares of Verona Pharma from $60.00 to $75.00 and gave the stock a "buy" rating in a research note on Friday, February 28th. Roth Mkm started coverage on shares of Verona Pharma in a research report on Friday, January 10th. They issued a "buy" rating and a $68.00 target price for the company. Finally, Roth Capital set a $83.00 price target on shares of Verona Pharma in a research report on Friday, February 28th. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Verona Pharma has an average rating of "Buy" and a consensus target price of $75.43.

Verona Pharma Stock Up 3.2 %

VRNA stock opened at $62.01 on Wednesday. The stock has a market capitalization of $5.01 billion, a P/E ratio of -32.30 and a beta of 0.16. Verona Pharma has a 52 week low of $11.39 and a 52 week high of $70.40. The firm has a 50-day simple moving average of $62.38 and a 200-day simple moving average of $50.00. The company has a quick ratio of 12.88, a current ratio of 13.03 and a debt-to-equity ratio of 0.93.

Insider Transactions at Verona Pharma

In related news, insider Kathleen A. Rickard sold 79,264 shares of the stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $8.35, for a total value of $661,854.40. Following the completion of the transaction, the insider now directly owns 2,608,976 shares in the company, valued at approximately $21,784,949.60. This represents a 2.95 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 4.80% of the company's stock.

Hedge Funds Weigh In On Verona Pharma

Large investors have recently modified their holdings of the business. Shilanski & Associates Inc. purchased a new stake in Verona Pharma in the 4th quarter valued at about $305,000. Values First Advisors Inc. raised its stake in shares of Verona Pharma by 36.9% in the 4th quarter. Values First Advisors Inc. now owns 23,505 shares of the company's stock valued at $1,092,000 after acquiring an additional 6,331 shares during the period. Choreo LLC acquired a new position in shares of Verona Pharma in the 4th quarter worth approximately $230,000. Legato Capital Management LLC boosted its position in shares of Verona Pharma by 132.9% during the 4th quarter. Legato Capital Management LLC now owns 24,853 shares of the company's stock worth $1,154,000 after purchasing an additional 14,183 shares during the period. Finally, Hennion & Walsh Asset Management Inc. increased its holdings in Verona Pharma by 24.3% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 193,707 shares of the company's stock valued at $8,996,000 after purchasing an additional 37,872 shares during the last quarter. Institutional investors and hedge funds own 85.88% of the company's stock.

Verona Pharma Company Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.